Your browser doesn't support javascript.
loading
Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
Ladha, Abdullah; Hui, Gavin; Cheung, Edna; Berube, Caroline; Coutre, Steven E; Gotlib, Jason; Liedtke, Michaela; Zhang, Tian Y; Muffly, Lori; Mannis, Gabriel N.
Afiliação
  • Ladha A; Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Hui G; Department of Medicine, Stanford University, Stanford, CA, USA.
  • Cheung E; Department of Pharmacy, Stanford Health Care, Stanford, CA, USA.
  • Berube C; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Coutre SE; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Gotlib J; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Liedtke M; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Zhang TY; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Muffly L; Division of Blood and Marrow Transplantation, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
  • Mannis GN; Division of Hematology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Leuk Lymphoma ; 62(6): 1510-1513, 2021 06.
Article em En | MEDLINE | ID: mdl-33491527
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Aminoglicosídeos Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Aminoglicosídeos Idioma: En Ano de publicação: 2021 Tipo de documento: Article